Moving Beyond JAK Inhibitors in Myeloproliferative Neoplasms

1 Vues
administrator
administrator
07/29/23

Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.

  • Catégorie

Montre plus
0 commentaires Trier par

    Aucun commentaire trouvé

    Commentaires de Facebook

    Suivant

    Management of pleural mesothelioma after first line checkpoint inhibitors
    00:01:33
    Management of pleural mesothelioma after first line checkpoint inhibitors
    administrator
    2 Vues
    Moving Forward - Life After Anal Cancer
    00:13:18
    Moving Forward - Life After Anal Cancer
    administrator
    3 Vues
    High level breast prosthesis for mastectomy women sports moving dancing running...
    00:01:36
    High level breast prosthesis for mastectomy women sports moving dancing running...
    administrator
    2 Vues
    Story moving on the path of success in a case of desmoid tumor, spindle cell neoplasm & sarcoma
    00:01:39
    Story moving on the path of success in a case of desmoid tumor, spindle cell neoplasm & sarcoma
    administrator
    1 Vues
    NBE- MANAGEMENT OF APPENDIX NEOPLASMS & PMP- DR. ROHIT KUMAR
    00:54:02
    NBE- MANAGEMENT OF APPENDIX NEOPLASMS & PMP- DR. ROHIT KUMAR
    administrator
    5 Vues
    Karim Sarhane video - Learning Module: Appendicitis and Appendiceal Neoplasms
    00:01:41
    Karim Sarhane video - Learning Module: Appendicitis and Appendiceal Neoplasms
    administrator
    1 Vues
    Karim Sarhane video - Learning Module: Appendicitis and Appendiceal Neoplasms
    00:01:41
    Karim Sarhane video - Learning Module: Appendicitis and Appendiceal Neoplasms
    administrator
    3 Vues
    Appendix 10 ( Neoplasms of appendix ) , by Dr.Wahdan
    00:06:53
    Appendix 10 ( Neoplasms of appendix ) , by Dr.Wahdan
    administrator
    3 Vues
    Dr. Siegelman on Imaging of the Peritoneum and Appendiceal Neoplasms
    00:25:55
    Dr. Siegelman on Imaging of the Peritoneum and Appendiceal Neoplasms
    administrator
    4 Vues
    Future directions for checkpoint inhibitors in cutaneous lymphoma treatment
    00:01:35
    Future directions for checkpoint inhibitors in cutaneous lymphoma treatment
    administrator
    2 Vues
    Moving Beyond One Size Fits All for Angioimmunoblastic T-Cell Lymphoma
    00:49:37
    Moving Beyond One Size Fits All for Angioimmunoblastic T-Cell Lymphoma
    administrator
    5 Vues
    Immune checkpoint inhibitors for cutaneous T-cell lymphoma
    00:01:48
    Immune checkpoint inhibitors for cutaneous T-cell lymphoma
    administrator
    1 Vues
    Combining targeted agents with checkpoint inhibitors in cutaneous T-cell lymphoma
    00:01:33
    Combining targeted agents with checkpoint inhibitors in cutaneous T-cell lymphoma
    administrator
    2 Vues
    Increasing the efficacy of PD-1 inhibitors in HL using combination strategies
    00:01:06
    Increasing the efficacy of PD-1 inhibitors in HL using combination strategies
    administrator
    2 Vues
    The zebras of uterine mesenchymal neoplasms - Dr. Bennett (University of Chicago) #GYNPATH
    01:05:19
    The zebras of uterine mesenchymal neoplasms - Dr. Bennett (University of Chicago) #GYNPATH
    administrator
    2 Vues
    The side effects of BRAF/MEK inhibitors and how to manage them
    00:41:16
    The side effects of BRAF/MEK inhibitors and how to manage them
    administrator
    2 Vues
    Myeloproliferative Neoplasms (MPN) Education Foundation—Eliminating Fear With Compassion
    00:01:57
    Myeloproliferative Neoplasms (MPN) Education Foundation—Eliminating Fear With Compassion
    administrator
    5 Vues
    Medical School Pathology: Introduction to Myeloid Neoplasms
    00:19:43
    Medical School Pathology: Introduction to Myeloid Neoplasms
    administrator
    1 Vues
    Srdan Verstovsek, ASH 2019: Individualized Management of Myeloproliferative neoplasms
    00:07:57
    Srdan Verstovsek, ASH 2019: Individualized Management of Myeloproliferative neoplasms
    administrator
    3 Vues